AIM ImmunoTech Inc.: AIM ImmunoTech Receives IND Clearance f

AIM ImmunoTech Inc.: AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen for the Treatment of Locally Advanced Pancreatic Cancer

Data seen to date indicates that Ampligen (rintatolimod) could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer In a single-center

Related Keywords

United States , Netherlands , American , Michaela Tony Hollingsworth , Kelsey Klute , Thomas Equels , Immunotech Inc , University Of Nebraska Medical Center , Buffett Cancer Center , Drug Administration , Early Access Program , Amarex Clinical Research , Erasmus Program , Netherlands At Erasmus Medical Center , Pancreatic Cancer Phase , Chief Executive Officer , Nebraska Medical Center , Clinical Research , Pancreato Biliary Surgeon , Progression Free Survival , Erasmus Medical , Private Securities Litigation Reform Act , Immunotech , Eceives , Clearance , Rom , Advance , Hase , Study , Ampligen , Treatment , Ocally , Dvanced , Pancreatic , Dancer ,